Homocystamide Conjugates of Human Serum Albumin as a Platform to Prepare Bimodal Multidrug Delivery Systems for Boron Neutron Capture Therapy

• Published in: Molecules (Basel, Switzerland) Vol. 26; no. 21; p. 6537
• Main Authors: Popova, Tatyana, Dymova, Maya A., Koroleva, Ludmila S., Zakharova, Olga D., Lisitskiy, Vladimir A., Raskolupova, Valeria I., Sycheva, Tatiana, Taskaev, Sergei, Silnikov, Vladimir N., Godovikova, Tatyana S.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 29.10.2021; MDPI
• Subjects: Antineoplastic Agents - chemical synthesis; Antineoplastic Agents - chemistry; Antineoplastic Agents - therapeutic use; Biodistribution; Boron; Boron Compounds - chemical synthesis; Boron Compounds - chemistry; Boron Compounds - therapeutic use; boron delivery agents; Boron Neutron Capture Therapy; boronated albumin theranostic; Brain cancer; Cancer therapies; Cell Line, Tumor; Cell Proliferation - drug effects; Cell Survival - drug effects; Chemotherapy; conjugate; Cytotoxicity; Drug Delivery Systems; Drug Screening Assays, Antitumor; Drugs; Fluorine; Glioma; Homocysteine - analogs & derivatives; Homocysteine - chemistry; Humans; Hyperglycemia; in vitro efficacy evaluation; Magnetic resonance imaging; Molecular Structure; Proteins; Radiation; Serum Albumin, Human - chemistry; thenoyltrifluoroacetone; Tumors; conjugate; boron neutron capture therapy; thenoyltrifluoroacetone; colony forming assay; boronated albumin theranostic; irradiated by epithermal neutron flux; in vitro efficacy evaluation; boron delivery agents

Boron neutron capture therapy is a unique form of adjuvant cancer therapy for various malignancies including malignant gliomas. The conjugation of boron compounds and human serum albumin (HSA)—a carrier protein with a long plasma half-life—is expected to extend systemic circulation of the boron comp...